US$ 23.88
fda and tirzepatide Says Compounded Must Exit the Market F.D.A. Approves New Obesity Drug
Description
$249 per month, no matter the dose

Some will use Liver-Rx

In the future, this finding should be extrapolated to traditional long-term cost-effectiveness analysis, using common outcomes such as quality-adjusted life years.

Or a Different Beast Entirely